Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

根据Bernstein的分析，Eli Lilly（LLY）在选举后的下跌可能被夸大了，因为当选总统特朗普的一位亲密盟友似乎支持减肥药物。这家制药公司的股票自选举日以来已下跌超过6%，这也导致了整个行业许多公司股价下跌的部分因素。特朗普宣布将Robert F. Kennedy Jr.任命为领导卫生与公共服务部的候选人后，Eli ...

GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

GlobalData analysis sees Lilly's investment in UK life sciences as an opportunity to drive economic growth whilst improving public health.

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Mercks Keytruda tops global pharmaceutical sales as Humira drops out of top 10 Mercks cancer drug dominates global sales ...